文献速递瓣膜病与结构性心脏病

经腔静脉途径行经导管主动脉瓣置换术的前瞻性研究

Transcaval Access and Closure for Transcatheter Aortic Valve Replacement: A Prospective Investigation.
PubMed 文献 · J Am Coll Cardiol · 2016-10-29

这项前瞻性、独立裁定、多中心、单臂试验纳入100例不适合股动脉入路且经胸入路风险高或禁忌的患者,尝试经腔静脉入路行TAVR。99例入路成功,98例装置成功,住院生存率96%,30天生存率92%,VARC-2危及生命出血7%、改良VARC-2主要血管并发症13%。作者认为出血和血管并发症常见但在该高危队列可接受,建议在适合经胸入路的患者中进一步研究。

要点

  • 经腔静脉入路在99/100例不适合股动脉入路患者中成功实施。
  • 装置成功98/99例,住院生存率96%,30天生存率92%。
  • VARC-2危及生命出血7%,改良VARC-2主要血管并发症13%。

核心结论

  • 经腔静脉入路使不适合经胸入路的患者得以行TAVR。
  • 使用可透过性镍钛心脏封堵器闭合入路端口时,出血和血管并发症常见但在该高危队列可接受。
  • 作者建议在适合经胸入路的患者中研究经腔静脉入路。
  • 专为闭合设计的装置正在研发中,可能简化操作并减少出血。

研究设计与样本

  • 前瞻性、独立裁定、多中心、单臂试验,纳入100例不适合股动脉入路且经胸入路并发症风险高或禁忌的患者。
  • 经腔静脉入路通过电灼腔静脉导丝并推进至预先放置的主动脉圈套器内进入腹主动脉。
  • 交换为硬导丝后通过经腔静脉导入鞘行常规TAVR,入路端口用镍钛心脏封堵器闭合。
  • 核心实验室分析出院前和30天腹部计算机断层扫描。
  • 胸外科医师学会预测死亡风险为9.6 ± 6.3%。

主要发现

  • 经腔静脉入路在100例患者中99例成功。
  • 装置成功(入路和闭合使用镍钛心脏封堵器且无死亡或紧急外科挽救)在99例中98例发生;1例受试者使用覆膜支架闭合。
  • 住院生存率为96%,30天生存率为92%。
  • 第二版瓣膜学术研究联盟(VARC-2)危及生命出血和可能与经腔静脉入路相关的改良VARC-2主要血管并发症分别为7%和13%。
  • 中位住院时间为4天(范围2至6天),出院后无血管并发症。

关键数值与推荐

  • 胸外科医师学会预测死亡风险为9.6 ± 6.3%。
  • 经腔静脉入路成功99/100例,装置成功98/99例。
  • 住院生存率96%,30天生存率92%。
  • VARC-2危及生命出血7%,改良VARC-2主要血管并发症13%。
  • 中位住院时间4天(范围2至6天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcaval access may enable fully percutaneous transcatheter aortic valve replacement (TAVR) without the hazards and discomfort of transthoracic (transapical or transaortic) access. OBJECTIVES: The authors performed a prospective, independently adjudicated, multicenter, single-arm trial of transcaval access for TAVR in patients who were ineligible for femoral artery access and had high or prohibitive risk of complications from transthoracic access. METHODS: A total of 100 patients underwent attempted percutaneous transcaval access to the abdominal aorta by electrifying a caval guidewire and advancing it into a pre-positioned aortic snare. After exchanging for a rigid guidewire, conventional TAVR was performed through transcaval introducer sheaths. Transcaval access ports were closed with nitinol cardiac occluders. A core laboratory analyzed pre-discharge and 30-day abdominal computed tomograms. The Society of Thoracic Surgeons predicted risk of mortality was 9.6 ± 6.3%. RESULTS: Transcaval access was successful in 99 of 100 patients. Device success (access and closure with a nitinol cardiac occluder without death or emergency surgical rescue) occurred 98 of 99 patients; 1 subject had closure with a covered stent. Inpatient survival was 96%, and 30-day survival was 92%. Second Valve Academic Research Consortium (VARC-2) life-threatening bleeding and modified VARC-2 major vascular complications possibly related to transcaval access were 7% and 13%, respectively. Median length of stay was 4 days (range 2 to 6 days). There were no vascular complications after discharge. CONCLUSIONS: Transcaval access enabled TAVR in patients who were not good candidates for transthoracic access. Bleeding and vascular complications, using permeable nitinol cardiac occluders to close the access ports, were common but acceptable in this high-risk cohort. Transcaval access should be investigated in patients who are eligible for transthoracic access. Purpose-built closure devices are in development that may simplify the procedure and reduce bleeding. (Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access; NCT02280824).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Greenbaum AB, Babaliaros VC, Chen MY, et al. Transcaval Access and Closure for Transcatheter Aortic Valve Replacement: A Prospective Investigation. J Am Coll Cardiol. 2016. PMID: 27989885. doi:10.1016/j.jacc.2016.10.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。